See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
The Oscars
Volodymyr Zelenskyy
Ukraine War
Artificial Intelligence
Social Media
Donald Trump
European Union
US Politics
Rugby
Climate Change
European Politics
Cricket
Published • loading... • Updated

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

Summary by PR Newswire
- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy -

2 Articles

All
Left
Center
1
Right
PR NewswirePR Newswire

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy -

·United States
Read Full Article
onclive.comonclive.com

Beyond Serum Tryptase: Exploring Additional Testing Approaches for Indolent Systemic Mastocytosis

Tracy I. George, MD, discusses testing considerations in indolent systemic mastocytosis, including the role of serum tryptase and KIT D816V testing.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

onclive.com broke the news in on Friday, February 28, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal